Contents
03 July 2019
Vol 11, Issue 499
Vol 11, Issue 499
Perspective
- Design of vaccine efficacy trials during public health emergencies
This Perspective describes key considerations for the design and analysis of candidate vaccine trials during public health emergencies.
Research Articles
- Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies
Agonism of CD11b overcomes myeloid cell–induced immunosuppression to render pancreatic cancer models responsive to checkpoint immunotherapy.
- CFTR-PTEN–dependent mitochondrial metabolic dysfunction promotes Pseudomonas aeruginosa airway infection
Excess succinate due to CFTR-PTEN dysfunction selects for Pseudomonas aeruginosa mutants adapted to the airway.
- Retinol binding protein 3 is increased in the retina of patients with diabetes resistant to diabetic retinopathy
Retinol binding protein 3 may protect against the progression of diabetic retinopathy by inhibiting glucose uptake into retinal cells.
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Dasatinib is a pharmacologic switch for CARs that enables physicians to control CAR T cell function in real time.
- Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species
Imaging reveals that antiretroviral drugs are not distributed evenly in the mammalian gut, with potential implications for HIV replication.
Editors' Choice
- Doubling-down on prion protein function in Alzheimer’s disease
The prion protein functions as a carrier for delivering Aβ to exosomes during Alzheimer’s disease.
- Live and let die
Death and replacement of microglia is required for effective remyelination of damaged axons.
- p21: One protein to rule cell fate
Early p21 expression controls cells’ proliferation/senescence fate after chemotherapy.
- A new player in hunger games
Hypoleptinemia-mediated food intake requires the activation of the hypothalamic-pituitary-adrenal axis.
About The Cover
ONLINE COVER Inviting T Cells In. Pancreatic ductal adenocarcinoma is typically resistant to immunotherapy, in part because myeloid cells in the tumor prevent T cells (brown) from contacting and eliminating tumor cells (magenta). To overcome this obstacle, Panni et al. tested a small molecule agonist of CD11b, an integrin that is widely expressed on myeloid cells. The drug modified myeloid cell phenotypes and recruitment, which in turn enhanced T cell responses in implanted or genetically engineered murine pancreatic tumor models. Combining the CD11b agonist with treatments such as chemotherapy or checkpoint blockade led to tumor regression and survival in these models. [CREDIT: SAMARTH HEGDE AND DAVID DENARDO/WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, ST. LOUIS]
